

# Inder S Anand

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7807288/inder-s-anand-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

322 papers	25,826 citations	82 h-index	154 g-index
346 ext. papers	32,733 ext. citations	8.3 avg, IF	6.61 L-index

#	Paper	IF	Citations
322	Dose-limiting, adverse event-associated bradycardia with $\beta$ -blocker treatment of atrial fibrillation in the GENETIC-AF trial.. <i>Heart Rhythm</i> <b>2022</b> , 3, 40-49	1.5	
321	Persistent Autonomic Engagement and Cardiac Control After Four or More Years of Autonomic Regulation Therapy Using Vagus Nerve Stimulation.. <i>Frontiers in Physiology</i> , <b>2022</b> , 13, 853617	4.6	
320	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.. <i>JACC: Heart Failure</i> , <b>2022</b> , 10, 336-346	7.9	0
319	Diabetes and prediabetes in patients with heart failure and preserved ejection fraction.. <i>European Journal of Heart Failure</i> , <b>2021</b> ,	12.3	3
318	A Systematic Review and Network-Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction.. <i>JACC: Heart Failure</i> , <b>2021</b> ,	7.9	14
317	Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients with Heart Failure with Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. <i>Circulation</i> , <b>2021</b> ,	16.7	1
316	Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HF. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e021494	6.4	0
315	Readmissions, Death and Its Associated Predictors in Heart Failure With Preserved Versus Reduced Ejection Fraction. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e021414	6	0
314	Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , <b>2021</b> , 14, e008293	7.6	2
313	Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2021</b> ,	16.2	9
312	Therapeutic responsiveness to vagus nerve stimulation in patients receiving beta-blockade for heart failure with reduced ejection fraction. <i>IJC Heart and Vasculature</i> , <b>2021</b> , 37, 100888	2.4	1
311	Effect of dapagliflozin on anaemia in DAPA-HF. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 617-628	12.3	14
310	Re-appraisal of the obesity paradox in heart failure: a meta-analysis of individual data. <i>Clinical Research in Cardiology</i> , <b>2021</b> , 110, 1280-1291	6.1	5
309	Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis. <i>Circulation: Heart Failure</i> , <b>2021</b> , 14, e008052	7.6	4
308	Electroanatomic Ratios and Mortality in Patients With Heart Failure: Insights from the ASIAN-HF Registry. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e017932	6	1
307	Incidence and Outcomes of Pneumonia in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 1961-1973	15.1	7
306	Socioeconomic Status and Outcomes in Heart Failure With Reduced Ejection Fraction From Asia. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2021</b> , 14, e006962	5.8	3

305	Global Differences in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , <b>2021</b> , 14, e007901	7.6	2
304	Burden of Heart Failure Signs and Symptoms, Prognosis, and Response to Therapy: The PARAGON-HF Trial. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 386-397	7.9	2
303	Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. <i>Circulation</i> , <b>2021</b> , 143, 326-336	16.7	74
302	Long-term Follow-Up of Patients with Heart Failure and Reduced Ejection Fraction Receiving Autonomic Regulation Therapy in the ANTHEM-HF Pilot Study. <i>International Journal of Cardiology</i> , <b>2021</b> , 323, 175-178	3.2	11
301	Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF. <i>Circulation</i> , <b>2021</b> , 143, 298-309	16.7	69
300	Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 105-116	59.2	164
299	Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction. <i>Clinical Research in Cardiology</i> , <b>2021</b> , 110, 1234-1248	6.1	3
298	Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2021</b> , 325, 39-49	27.4	22
297	Pulse Pressure, Prognosis, and Influence of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction. <i>Hypertension</i> , <b>2021</b> , 77, 546-556	8.5	7
296	Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 776-784	12.3	3
295	Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the Arg389Arg Genotype. <i>Circulation: Arrhythmia and Electrophysiology</i> , <b>2021</b> , 14, e009591	6.4	1
294	Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. <i>European Heart Journal</i> , <b>2021</b> , 42, 3741-3752	9.5	13
293	Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. <i>Circulation</i> , <b>2021</b> , 144, 1284-1294	16.7	30
292	Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e022069	6	4
291	NT-proBNP for Risk Prediction in Heart Failure: Identification of Optimal Cutoffs Across Body Mass Index Categories. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 653-663	7.9	1
290	41 Circulating levels and prognostic cut-offs of sST2, high-sensitivity troponin T, and NT-proBNP in women vs. men with chronic heart failure. <i>European Heart Journal Supplements</i> , <b>2021</b> , 23,	1.5	1
289	Prevalence and Prognostic Significance of Frailty in Asian Patients With Heart Failure. <i>JACC Asia</i> , <b>2021</b> , 1, 303-313		1
288	Ethnic differences in atrial fibrillation among patients with heart failure in Asia. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 1419-1429	3.7	4

287	Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials. <i>JACC: Heart Failure</i> , <b>2020</b> , 8, 618-626	7.9	6
286	Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1247-1258	12.3	19
285	Baseline NT-proBNP and responsiveness to autonomic regulation therapy in patients with heart failure and reduced ejection fraction. <i>IJC Heart and Vasculature</i> , <b>2020</b> , 29, 100520	2.4	3
284	Comparison of symptomatic and functional responses to vagus nerve stimulation in ANTHEM-HF, INOVATE-HF, and NECTAR-HF. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 75-83	3.7	23
283	Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 1644-1656	15.1	23
282	Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 323, 1353-1368	27.4	155
281	Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , <b>2020</b> , 8, 372-381	7.9	25
280	Effects of combined renin-angiotensin-aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT-CHF and ASIAN-HF registries. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1472-1482	12.3	14
279	Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction: A TOPCAT Biorepository Study. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e006638	7.6	3
278	How I treat anemia in heart failure. <i>Blood</i> , <b>2020</b> , 136, 790-800	2.2	5
277	Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trial. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 557-559	12.3	3
276	Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 2078-2088	12.3	15
275	Potassium abnormalities in patients with heart failure from 11 Asian regions: insights from the ASIAN-HF registry. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 751-754	12.3	1
274	Association between body surface area and prescribed doses of guideline-directed medications among international patients with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 754-758	12.3	3
273	Modeling defibrillation benefit for survival among cardiac resynchronization therapy defibrillator recipients. <i>American Heart Journal</i> , <b>2020</b> , 222, 93-104	4.9	0
272	Regional Variation of Mortality in Heart Failure With Reduced and Preserved Ejection Fraction Across Asia: Outcomes in the ASIAN-HF Registry. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e012199	6.1	22
271	Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF. <i>Circulation</i> , <b>2020</b> , 141, 338-351	16.7	122
270	Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. <i>Circulation</i> , <b>2020</b> , 141, 352-361	16.7	145

269	Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 2160-2171	12.3	24
268	Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. <i>Circulation</i> , <b>2020</b> , 142, 1040-1054	16.7	52
267	Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF. <i>Circulation</i> , <b>2020</b> , 142, 1623-1632	16.7	20
266	Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 2093-2101	12.3	15
265	Patient-reported outcomes in heart failure with preserved vs. reduced ejection fraction: focus on physical independence. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 2051-2062	3.7	2
264	Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). <i>European Heart Journal</i> , <b>2020</b> , 41, 3402-3418 <sup>40</sup>	9.5	40
263	Biomarkers Enhance Discrimination and Prognosis of Type 2 Myocardial Infarction. <i>Circulation</i> , <b>2020</b> , 142, 1532-1544	16.7	14
262	Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. <i>Lancet, The</i> , <b>2019</b> , 394, 1254-1263	4.0	83
261	Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 1609-1620	59.2	705
260	Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 1995-2008	59.2	2021
259	Association of obesity with heart failure outcomes in 11 Asian regions: A cohort study. <i>PLoS Medicine</i> , <b>2019</b> , 16, e1002916	11.6	26
258	Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , <b>2019</b> , 12, e006125	7.6	10
257	Revisiting the obesity paradox in heart failure: Per cent body fat as predictor of biomarkers and outcome. <i>European Journal of Preventive Cardiology</i> , <b>2019</b> , 26, 1751-1759	3.9	17
256	Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , <b>2019</b> , 7, 418-427	7.9	10
255	Prescription patterns of anti-diabetic medications and clinical outcomes in Asian patients with heart failure and diabetes mellitus. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 685-688	12.3	5
254	A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 665-675	12.3	145
253	N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status. <i>Circulation: Heart Failure</i> , <b>2019</b> , 12, e005766	7.6	14
252	T cell and monocyte/macrophage activation markers associate with adverse outcome, but give limited prognostic value in anemic patients with heart failure: results from RED-HF. <i>Clinical Research in Cardiology</i> , <b>2019</b> , 108, 133-141	6.1	4

251	Heart failure with preserved ejection fraction in Asia. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 23-36	12.3	64
250	Copeptin to rule out myocardial infarction in Blacks versus Caucasians. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2019</b> , 8, 395-403	4.3	3
249	Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , <b>2019</b> , 8, e013114	6	38
248	Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1270-1278	12.3	73
247	Microvascular Disease in Patients With Diabetes With Heart Failure and Reduced Ejection Versus Preserved Ejection Fraction. <i>Diabetes Care</i> , <b>2019</b> , 42, 1792-1799	14.6	25
246	Impact of Malnutrition Using Geriatric Nutritional Risk Index in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , <b>2019</b> , 7, 664-675	7.9	28
245	Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. <i>JACC: Heart Failure</i> , <b>2019</b> , 7, 862-874	7.9	40
244	Application of the H FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1288-1291	12.3	11
243	Background pharmacological therapy in the ANTHEM-HF: comparison to contemporary trials of novel heart failure therapies. <i>ESC Heart Failure</i> , <b>2019</b> , 6, 1052-1056	3.7	4
242	Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 601-612	15.1	40
241	Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 974-984	12.3	30
240	Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population: The GENETIC-AF Trial. <i>JACC: Heart Failure</i> , <b>2019</b> , 7, 586-598	7.9	13
239	Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1279-1287	12.3	133
238	Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure. <i>JACC: Heart Failure</i> , <b>2019</b> , 7, 1022-1028	7.9	2
237	Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , <b>2019</b> , 12, e006539	7.6	36
236	High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure. <i>International Journal of Cardiology</i> , <b>2019</b> , 277, 166-172	3.2	15
235	The biological variation of plasma proenkephalin: data from a stable heart failure cohort. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2019</b> , 57, e105-e107	5.9	1
234	Impact of diabetes and sex in heart failure with reduced ejection fraction patients from the ASIAN-HF registry. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 297-307	12.3	22



233	Comparison of Outcomes in Patients With Diabetes Mellitus Treated With Versus Without Insulin + Heart Failure With Preserved Left Ventricular Ejection Fraction (from the TOPCAT Study). <i>American Journal of Cardiology</i> , <b>2019</b> , 123, 611-617	3	14
232	Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 888-895	12.3	65
231	Sudden Death in Heart Failure With Preserved Ejection Fraction: A Competing Risks Analysis From the TOPCAT Trial. <i>JACC: Heart Failure</i> , <b>2018</b> , 6, 653-661	7.9	34
230	Prevalence, clinical correlates, and outcomes of anaemia in multi-ethnic Asian patients with heart failure with reduced ejection fraction. <i>ESC Heart Failure</i> , <b>2018</b> , 5, 570-578	3.7	16
229	Hyporesponsiveness to Darbepoetin Alfa in Patients With Heart Failure and Anemia in the RED-HF Study (Reduction of Events by Darbepoetin Alfa in Heart Failure): Clinical and Prognostic Associations. <i>Circulation: Heart Failure</i> , <b>2018</b> , 11, e004431	7.6	7
228	Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis. <i>Circulation</i> , <b>2018</b> , 137, 286-297	16.7	102
227	Autonomic regulation therapy to enhance myocardial function in heart failure patients: the ANTHEM-HFpEF study. <i>ESC Heart Failure</i> , <b>2018</b> , 5, 95-100	3.7	24
226	A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. <i>American Heart Journal</i> , <b>2018</b> , 199, 51-58	4.9	7
225	Utility of natriuretic peptides to assess and manage patients with heart failure receiving angiotensin receptor blocker/neprilysin inhibitor therapy. <i>Postgraduate Medicine</i> , <b>2018</b> , 130, 299-307	3.7	13
224	Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial. <i>Circulation: Heart Failure</i> , <b>2018</b> , 11, e004457	7.6	20
223	Chronic obstructive pulmonary disease and $\beta$ -blocker treatment in Asian patients with heart failure. <i>ESC Heart Failure</i> , <b>2018</b> , 5, 297-305	3.7	7
222	Factors affecting seasonal changes in blood pressure in North India: A population based four-seasons study. <i>Indian Heart Journal</i> , <b>2018</b> , 70, 360-367	1.6	8
221	Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 268-277	12.3	25
220	Heart Failure With Recovered Ejection Fraction in African Americans: Results From the African-American Heart Failure Trial. <i>Journal of Cardiac Failure</i> , <b>2018</b> , 24, 303-309	3.3	10
219	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , <b>2018</b> , 11, e004962	7.6	70
218	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial. <i>JACC: Heart Failure</i> , <b>2018</b> , 6, 689-697	7.9	36
217	Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study. <i>The Lancet Global Health</i> , <b>2018</b> , 6, e1008-e1018	13.6	67
216	Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2018</b> , 3, 1000-1005	16.2	24

215	Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry. <i>PLoS Medicine</i> , <b>2018</b> , 15, e1002541	11.6	60
214	Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 483-490	12.3	17
213	Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 491-500	12.3	37
212	Cardiac Troponin I and Risk of Cardiac Events in Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , <b>2018</b> , 11, e005312	7.6	19
211	sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 72, 2309-2320	15.1	73
210	Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , <b>2018</b> , 11, e005288	7.6	23
209	Response by Anand and Gupta to Letter Regarding Article, "Anemia and Iron Deficiency in Heart Failure: Current Concepts and Emerging Therapies". <i>Circulation</i> , <b>2018</b> , 138, 2976-2977	16.7	1
208	Heart Failure With Preserved Ejection Fraction in the Young. <i>Circulation</i> , <b>2018</b> , 138, 2763-2773	16.7	29
207	High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial. <i>American Heart Journal</i> , <b>2018</b> , 202, 97-103	4.9	23
206	Stable but Progressive Nature of Heart Failure: Considerations for Primary Care Physicians. <i>American Journal of Cardiovascular Drugs</i> , <b>2018</b> , 18, 333-345	4	11
205	Anemia and Iron Deficiency in Heart Failure: Current Concepts and Emerging Therapies. <i>Circulation</i> , <b>2018</b> , 138, 80-98	16.7	150
204	Multi-ethnic comparisons of diabetes in heart failure with reduced ejection fraction: insights from the HF-ACTION trial and the ASIAN-HF registry. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 1281-1289	12.3	20
203	Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. <i>Circulation</i> , <b>2017</b> , 135, e1054-e1091	16.7	274
202	Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist). <i>Circulation</i> , <b>2017</b> , 136, 982-992	16.7	55
201	Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 2606-2618	15.1	47
200	Prognostic importance of left ventricular mechanical dyssynchrony in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 1043-1052	12.3	22
199	Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial. <i>JACC: Heart Failure</i> , <b>2017</b> , 5, 241-252	7.9	90
198	Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). <i>Circulation</i> , <b>2017</b> , 135, 724-735	16.7	100



197	Prognostic Importance of Temporal Changes in Resting Heart Rate in Heart Failure and Preserved Ejection Fraction: From the TOPCAT Study. <i>JACC: Heart Failure</i> , <b>2017</b> , 5, 782-791	7.9	18
196	Trend in prevalence of coronary artery disease and risk factors over two decades in rural Punjab. <i>Heart Asia</i> , <b>2017</b> , 9, e010938	1.9	15
195	Fixed-Dose Versus Off-Label Combination of Isosorbide Dinitrate Plus Hydralazine Hydrochloride: Retrospective Propensity-Matched Analysis in Black Medicare Patients with Heart Failure. <i>Advances in Therapy</i> , <b>2017</b> , 34, 1976-1988	4.1	3
194	Post-Extrasystolic Potentiation as a Predictor of Recovery of Left Ventricular Dysfunction After Radiofrequency Catheter Ablation. <i>JACC: Clinical Electrophysiology</i> , <b>2017</b> , 3, 1283-1291	4.6	6
193	Disparity Between Indications for and Utilization of Implantable Cardioverter Defibrillators in Asian Patients With Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2017</b> , 10,	5.8	17
192	Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. <i>JACC: Heart Failure</i> , <b>2017</b> , 5, 471-482	7.9	176
191	Multinational and multiethnic variations in health-related quality of life in patients with chronic heart failure. <i>American Heart Journal</i> , <b>2017</b> , 191, 75-81	4.9	23
190	Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure: A Meta-Analysis. <i>JACC: Heart Failure</i> , <b>2017</b> , 5, 280-286	7.9	89
189	Necessity of hospitalization and stress testing in low risk chest pain patients. <i>American Journal of Emergency Medicine</i> , <b>2017</b> , 35, 274-280	2.9	3
188	Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , <b>2017</b> , 23, 20-28	3.3	20
187	Structural Remodeling in the Development of Chronic Systolic Heart Failure: Implication for Treatment <b>2017</b> , 247-265		
186	Serial sampling of copeptin levels improves diagnosis and risk stratification in patients presenting with chest pain: results from the CHOPIN trial. <i>Emergency Medicine Journal</i> , <b>2016</b> , 33, 23-9	1.5	8
185	Heart Failure With Improved Ejection Fraction: Clinical Characteristics, Correlates of Recovery, and Survival: Results From the Valsartan Heart Failure Trial. <i>Circulation: Heart Failure</i> , <b>2016</b> , 9,	7.6	51
184	Extended Follow-Up of Patients With Heart Failure Receiving Autonomic Regulation Therapy in the ANTHEM-HF Study. <i>Journal of Cardiac Failure</i> , <b>2016</b> , 22, 639-42	3.3	66
183	Clinical neurocardiology defining the value of neuroscience-based cardiovascular therapeutics. <i>Journal of Physiology</i> , <b>2016</b> , 594, 3911-54	3.9	131
182	Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. <i>European Heart Journal</i> , <b>2016</b> , 37, 455-62	9.5	217
181	Aquapheresis Versus Intravenous Diuretics and Hospitalizations for Heart Failure. <i>JACC: Heart Failure</i> , <b>2016</b> , 4, 95-105	7.9	100
180	Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 1021-31	12.3	13

179	Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , <b>2016</b> , 9, e002763	7.6	147
178	QRS Duration Is a Predictor of Adverse Outcomes in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , <b>2016</b> , 4, 477-86	7.9	24
177	Regional and ethnic differences among patients with heart failure in Asia: the Asian sudden cardiac death in heart failure registry. <i>European Heart Journal</i> , <b>2016</b> , 37, 3141-3153	9.5	97
176	Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 1193-2023	12.3	135
175	The Post-Myocardial Infarction Pacing Remodeling Prevention Therapy (PRomPT) Trial: Design and Rationale. <i>Journal of Cardiac Failure</i> , <b>2015</b> , 21, 601-7	3.3	2
174	Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. <i>Circulation</i> , <b>2015</b> , 132, 402-14	16.7	263
173	Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 169-76	12.3	25
172	Calculated plasma volume status and prognosis in chronic heart failure. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 35-43	12.3	71
171	The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction). <i>JACC: Heart Failure</i> , <b>2015</b> , 3, 429-441	7.9	48
170	Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina: Analysis of the Irbesartan in Patients With Heart Failure and Preserved Systolic Function Trial. <i>Circulation: Heart Failure</i> , <b>2015</b> , 8, 717-24	7.6	15
169	Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. <i>Circulation: Heart Failure</i> , <b>2015</b> , 8, 1052-8	7.6	54
168	A novel method to predict the proportional risk of sudden cardiac death in heart failure: Derivation of the Seattle Proportional Risk Model. <i>Heart Rhythm</i> , <b>2015</b> , 12, 2069-77	6.7	52
167	Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , <b>2015</b> , 3, 478-486	7.9	17
166	Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 809-17	12.3	45
165	Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 1201-7	12.3	23
164	Midregional proadrenomedullin predicts mortality and major adverse cardiac events in patients presenting with chest pain: results from the CHOPIN trial. <i>Academic Emergency Medicine</i> , <b>2015</b> , 22, 554-634	3.4	10
163	ENCORE: Extension of the ANTHEM-HF Study Evaluating Autonomic Regulation Therapy in Reduced Ejection Fraction Heart Failure. <i>Journal of Cardiac Failure</i> , <b>2015</b> , 21, 940	3.3	5
162	Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 925-35	12.3	120

161	Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trials. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 424-33	12.3	79
160	Mortality prediction using a modified Seattle Heart Failure Model may improve patient selection for ventricular tachycardia ablation. <i>American Heart Journal</i> , <b>2015</b> , 170, 1099-104	4.9	16
159	Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. <i>Circulation</i> , <b>2015</b> , 131, 34-42	16.7	534
158	Spironolactone for heart failure with preserved ejection fraction. <i>New England Journal of Medicine</i> , <b>2014</b> , 370, 1383-92	59.2	1365
157	Effect of fixed-dose combination of isosorbide dinitrate and hydralazine on all hospitalizations and on 30-day readmission rates in patients with heart failure: results from the African-American Heart Failure Trial. <i>Circulation: Heart Failure</i> , <b>2014</b> , 7, 759-65	7.6	14
156	A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , <b>2014</b> , 16, 1175-82	12.3	53
155	Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). <i>European Journal of Heart Failure</i> , <b>2014</b> , 16, 778-87	12.3	60
154	Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 1106-13	15.1	48
153	Autonomic Regulation Therapy Titration Methodology Accelerates Adaptation to Low-Intensity Vagus Nerve Stimulation. <i>Journal of Cardiac Failure</i> , <b>2014</b> , 20, S71	3.3	2
152	Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American Heart Failure Trial. <i>American Journal of Cardiology</i> , <b>2014</b> , 114, 151-9	3	18
151	Impact of renal dysfunction on the Seattle Heart Failure Model. <i>Journal of Heart and Lung Transplantation</i> , <b>2014</b> , 33, 163-9	5.8	4
150	Autonomic regulation therapy via left or right cervical vagus nerve stimulation in patients with chronic heart failure: results of the ANTHEM-HF trial. <i>Journal of Cardiac Failure</i> , <b>2014</b> , 20, 808-16	3.3	204
149	History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. <i>Circulation: Heart Failure</i> , <b>2014</b> , 7, 960-6	7.6	28
148	Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. <i>Circulation: Heart Failure</i> , <b>2014</b> , 7, 104-15	7.6	174
147	Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. <i>Circulation: Heart Failure</i> , <b>2014</b> , 7, 740-51	7.6	159
146	Prognostic value of soluble ST2 in the Valsartan Heart Failure Trial. <i>Circulation: Heart Failure</i> , <b>2014</b> , 7, 418-26	7.6	95
145	Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. <i>Circulation: Heart Failure</i> , <b>2014</b> , 7, 573-9	7.6	112
144	Copeptin helps in the early detection of patients with acute myocardial infarction: primary results of the CHOPIN trial (Copeptin Helps in the early detection Of Patients with acute myocardial INfarction). <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 62, 150-160	15.1	127

143	Atrial fibrillation impairs the diagnostic performance of cardiac natriuretic peptides in dyspneic patients: results from the BACH Study (Biomarkers in ACute Heart Failure). <i>JACC: Heart Failure</i> , <b>2013</b> , 1, 192-9	7.9	76
142	Incidence of appropriate shock in implantable cardioverter-defibrillator patients with improved ejection fraction. <i>Journal of Cardiac Failure</i> , <b>2013</b> , 19, 426-30	3.3	43
141	Improvement of left ventricular diastolic function and left atrial reverse remodeling after catheter ablation of premature ventricular complexes. <i>Journal of Interventional Cardiac Electrophysiology</i> , <b>2013</b> , 38, 179-85	2.4	10
140	Autonomic regulation therapy for the improvement of left ventricular function and heart failure symptoms: the ANTHEM-HF study. <i>Journal of Cardiac Failure</i> , <b>2013</b> , 19, 655-60	3.3	51
139	Prevention of atrial fibrillation by bucindolol is dependent on the beta <sub>1</sub> Arg/Gly adrenergic receptor polymorphism. <i>JACC: Heart Failure</i> , <b>2013</b> , 1, 338-344	7.9	39
138	Treatment of anemia with darbepoetin alfa in systolic heart failure. <i>New England Journal of Medicine</i> , <b>2013</b> , 368, 1210-9	59.2	331
137	Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. <i>Circulation: Heart Failure</i> , <b>2013</b> , 6, 184-92	7.6	122
136	Mid-regional pro-adrenomedullin improves disposition strategies for patients with acute dyspnoea: results from the BACH trial. <i>Emergency Medicine Journal</i> , <b>2013</b> , 30, 633-7	1.5	11
135	Cardiorenal syndrome: a cardiologist's perspective of pathophysiology. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2013</b> , 8, 1800-7	6.9	23
134	Race influences the safety and efficacy of spironolactone in severe heart failure. <i>Circulation: Heart Failure</i> , <b>2013</b> , 6, 970-6	7.6	27
133	Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 511-8	12.3	111
132	Asian Sudden Cardiac Death in Heart Failure (ASIAN-HF) registry. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 928-36	12.3	54
131	Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF). <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 334-41	12.3	20
130	Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 324-33	12.3	29
129	Monitoring changes in fluid status with a wireless multisensor monitor: results from the Fluid Removal During Adherent Renal Monitoring (FARM) study. <i>Congestive Heart Failure</i> , <b>2012</b> , 18, 32-6		7
128	The effect of diabetes on the diagnostic and prognostic performance of mid-region pro-atrial natriuretic peptide and mid-region pro-adrenomedullin in patients with acute dyspnea. <i>Biomarkers</i> , <b>2012</b> , 17, 490-7	2.6	4
127	2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. <i>Europace</i> , <b>2012</b> , 14, 1236-86	3.9	195
126	Cardiac resynchronization therapy in the real world: comparison with the COMPANION study. <i>Journal of Cardiac Failure</i> , <b>2012</b> , 18, 153-8	3.3	7

125	The Heart Failure Society of America in 2020: a vision for the future. <i>Journal of Cardiac Failure</i> , <b>2012</b> , 18, 90-3	3.3	0
124	Design and performance of a multisensor heart failure monitoring algorithm: results from the multisensor monitoring in congestive heart failure (MUSIC) study. <i>Journal of Cardiac Failure</i> , <b>2012</b> , 18, 289-95	3.3	44
123	Prospective evaluation of elastic restraint to lessen the effects of heart failure (PEERLESS-HF) trial. <i>Journal of Cardiac Failure</i> , <b>2012</b> , 18, 446-58	3.3	26
122	Randomized controlled trial of ventricular elastic support therapy in the treatment of symptomatic heart failure: rationale and design. <i>American Heart Journal</i> , <b>2012</b> , 164, 638-45	4.9	5
121	Sudden cardiac death in heart failure patients with preserved ejection fraction. <i>Journal of Cardiac Failure</i> , <b>2012</b> , 18, 749-54	3.3	45
120	Biomarkers. <i>Heart Failure Clinics</i> , <b>2012</b> , 8, 207-24	3.3	7
119	Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. <i>Circulation: Heart Failure</i> , <b>2012</b> , 5, 571-8	7.6	129
118	Influence of age, race, sex, and body mass index on interpretation of midregional pro atrial natriuretic peptide for the diagnosis of acute heart failure: results from the BACH multinational study. <i>European Journal of Heart Failure</i> , <b>2012</b> , 14, 22-31	12.3	40
117	Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial. <i>European Journal of Heart Failure</i> , <b>2012</b> , 14, 278-86	12.3	99
116	Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials. <i>Circulation</i> , <b>2012</b> , 125, 280-8	16.7	177
115	Important differences in mode of death between men and women with heart failure who would qualify for a primary prevention implantable cardioverter-defibrillator. <i>Circulation</i> , <b>2012</b> , 126, 2402-7	16.7	47
114	Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial. <i>Circulation: Heart Failure</i> , <b>2012</b> , 5, 217-25	7.6	51
113	Combinatorial pharmacogenetic interactions of bucindolol and $\beta_1$ , $\beta_2$ adrenergic receptor polymorphisms. <i>PLoS ONE</i> , <b>2012</b> , 7, e44324	3.7	48
112	Cardiac resynchronization therapy in patients with minimal heart failure: a systematic review and meta-analysis. <i>Journal of the American College of Cardiology</i> , <b>2011</b> , 58, 935-41	15.1	54
111	Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. <i>Journal of the American College of Cardiology</i> , <b>2011</b> , 58, 1057-67	15.1	112
110	Design of the Multi-Sensor Monitoring in Congestive Heart Failure (MUSIC) study: prospective trial to assess the utility of continuous wireless physiologic monitoring in heart failure. <i>Journal of Cardiac Failure</i> , <b>2011</b> , 17, 11-6	3.3	21
109	Alterations in Ventricular Structure <b>2011</b> , 232-253		1
108	Telephone titration of heart failure medications. <i>Journal of Cardiovascular Nursing</i> , <b>2011</b> , 26, 29-36	2.1	8



107	Short-term mortality risk in emergency department acute heart failure. <i>Academic Emergency Medicine</i> , <b>2011</b> , 18, 947-58	3.4	56
106	Clinical trial report: Reevaluating telemonitoring in heart failure. <i>Current Heart Failure Reports</i> , <b>2011</b> , 8, 84-6	2.8	6
105	Biomarkers in kidney and heart disease. <i>Nephrology Dialysis Transplantation</i> , <b>2011</b> , 26, 62-74	4.3	38
104	Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. <i>Circulation: Heart Failure</i> , <b>2011</b> , 4, 561-8	7.6	80
103	Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. <i>Circulation: Heart Failure</i> , <b>2011</b> , 4, 324-31	7.6	168
102	Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. <i>Circulation: Heart Failure</i> , <b>2011</b> , 4, 569-77	7.6	173
101	Increased 90-day mortality in patients with acute heart failure with elevated copeptin: secondary results from the Biomarkers in Acute Heart Failure (BACH) study. <i>Circulation: Heart Failure</i> , <b>2011</b> , 4, 613-20	7.6	141
100	Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure. <i>PLoS ONE</i> , <b>2010</b> , 5, e9946	3.7	34
99	Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. <i>Circulation</i> , <b>2010</b> , 121, 1393-405	16.7	241
98	Research needed to support clinical use of biomarkers as prognostic indicators for patients with heart failure. <i>Cardiology Research and Practice</i> , <b>2010</b> , 2010, 453851	1.9	4
97	Definition and classification of Cardio-Renal Syndromes: workgroup statements from the 7th ADQI Consensus Conference. <i>Nephrology Dialysis Transplantation</i> , <b>2010</b> , 25, 1416-20	4.3	85
96	Prevention of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference. <i>Nephrology Dialysis Transplantation</i> , <b>2010</b> , 25, 1777-84	4.3	29
95	Epidemiology of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference. <i>Nephrology Dialysis Transplantation</i> , <b>2010</b> , 25, 1406-16	4.3	152
94	Cardiorenal syndromes: an executive summary from the consensus conference of the Acute Dialysis Quality Initiative (ADQI). <i>Contributions To Nephrology</i> , <b>2010</b> , 165, 54-67	1.6	85
93	Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. <i>Circulation</i> , <b>2010</b> , 122, 1387-95	16.7	214
92	Pathophysiology of anemia in heart failure. <i>Heart Failure Clinics</i> , <b>2010</b> , 6, 279-88	3.3	35
91	Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 55, 2062-76	15.1	389
90	Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy: data from the Valsartan Heart Failure Trial (Val-HeFT). <i>Journal of Cardiac Failure</i> , <b>2010</b> , 16, 964-70	3.3	48



89	Determination of hospitalization type by investigator case report form or adjudication committee in a large heart failure clinical trial (EBlocker Evaluation of Survival Trial [BEST]). <i>American Heart Journal</i> , <b>2010</b> , 160, 649-54	4.9	19
88	Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. <i>European Heart Journal</i> , <b>2010</b> , 31, 703-11	9.5	581
87	An update on cardiac troponins as circulating biomarkers in heart failure. <i>Current Heart Failure Reports</i> , <b>2010</b> , 7, 15-21	2.8	13
86	Treatment of anemia with darbepoetin alfa in heart failure. <i>Congestive Heart Failure</i> , <b>2010</b> , 16, 87-95		4
85	Digoxin use and heart failure outcomes: results from the Valsartan Heart Failure Trial (Val-HeFT). <i>Congestive Heart Failure</i> , <b>2010</b> , 16, 191-5		32
84	Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failure. <i>Vascular Health and Risk Management</i> , <b>2010</b> , 6, 449-55	4.4	6
83	Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population. <i>Circulation</i> , <b>2009</b> , 120, 835-42	16.7	165
82	Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure. <i>Circulation</i> , <b>2009</b> , 120, 1577-84	16.7	97
81	Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure: results from the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trial. <i>Circulation</i> , <b>2009</b> , 119, 969-77	16.7	121
80	DITPA (3,5-Diiodothyropropionic Acid), a thyroid hormone analog to treat heart failure: phase II trial veterans affairs cooperative study. <i>Circulation</i> , <b>2009</b> , 119, 3093-100	16.7	92
79	Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. <i>European Journal of Heart Failure</i> , <b>2009</b> , 11, 795-801	12.3	88
78	Relationship of quality of life scores with baseline characteristics and outcomes in the African-American heart failure trial. <i>Journal of Cardiac Failure</i> , <b>2009</b> , 15, 835-42	3.3	35
77	Carvedilol versus controlled-release metoprolol for elderly veterans with heart failure. <i>Journal of the American Geriatrics Society</i> , <b>2008</b> , 56, 1021-7	5.6	11
76	Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 52, 997-1003	15.1	252
75	Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 52, 2000-7	15.1	39
74	Anemia and chronic heart failure implications and treatment options. <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 52, 501-11	15.1	202
73	Traditional and novel approaches to management of heart failure: successes and failures. <i>Cardiology Clinics</i> , <b>2008</b> , 26, 59-72, vi	2.5	15
72	Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial. <i>Circulation: Heart Failure</i> , <b>2008</b> , 1, 34-42	7.6	33

71	Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. <i>Circulation</i> , <b>2008</b> , 117, 526-35	16.7	209
70	Heart failure and anemia: mechanisms and pathophysiology. <i>Heart Failure Reviews</i> , <b>2008</b> , 13, 379-86	5	57
69	Introduction: anemia in heart failure. <i>Heart Failure Reviews</i> , <b>2008</b> , 13, 377-8	5	2
68	Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. <i>Circulation</i> , <b>2007</b> , 116, 1242-9	16.7	533
67	Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial. <i>Journal of the American College of Cardiology</i> , <b>2007</b> , 49, 32-9	15.1	52
66	Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT. <i>Journal of Cardiac Failure</i> , <b>2007</b> , 13, 331-9	3.3	60
65	Effect of left ventricular scar size, location, and transmural extent on left ventricular remodeling with healed myocardial infarction. <i>American Journal of Cardiology</i> , <b>2007</b> , 99, 1109-14	3	117
64	Predicting survival in heart failure. <i>Current Cardiology Reports</i> , <b>2007</b> , 9, 209-17	4.2	1
63	Ventricular preexcitation modulates strain and attenuates cardiac remodeling in a swine model of myocardial infarction. <i>Circulation</i> , <b>2007</b> , 116, 1162-9	16.7	20
62	Prediction of mode of death in heart failure: the Seattle Heart Failure Model. <i>Circulation</i> , <b>2007</b> , 116, 392-8	16.7	218
61	Body mass index, prognosis and mode of death in chronic heart failure: results from the Valsartan Heart Failure Trial. <i>European Journal of Heart Failure</i> , <b>2007</b> , 9, 397-402	12.3	59
60	Plasma MMP-2, MMP-9 and N-BNP in long-term survivors following complicated myocardial infarction: relation to cardiac magnetic resonance imaging measures of left ventricular structure and function. <i>Journal of Cardiac Failure</i> , <b>2007</b> , 13, 843-9	3.3	35
59	Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial. <i>Journal of Cardiac Failure</i> , <b>2007</b> , 13, 797-804	3.3	66
58	Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT. <i>International Journal of Cardiology</i> , <b>2007</b> , 119, 48-53	3.2	57
57	The Seattle Heart Failure Model: prediction of survival in heart failure. <i>Circulation</i> , <b>2006</b> , 113, 1424-33	16.7	1394
56	Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. <i>Clinical Chemistry</i> , <b>2006</b> , 52, 1528-38	5.5	270
55	Relationships between clinical assessments and patients' perceptions of the effects of heart failure on their quality of life. <i>Journal of Cardiac Failure</i> , <b>2006</b> , 12, 87-92	3.3	97
54	Validation of a risk score for dying within 1 year of an admission for heart failure. <i>Journal of Cardiac Failure</i> , <b>2006</b> , 12, 276-80	3.3	22

53	The prognostic value of big endothelin-1 in more than 2,300 patients with heart failure enrolled in the Valsartan Heart Failure Trial (Val-HeFT). <i>Journal of Cardiac Failure</i> , <b>2006</b> , 12, 375-80	3.3	54
52	Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. <i>American Journal of Medicine</i> , <b>2006</b> , 119, 70.e23-30	2.4	82
51	Chronic heart failure with preserved left ventricular ejection fraction: diagnostic and prognostic value of left atrial size. <i>International Journal of Cardiology</i> , <b>2006</b> , 110, 386-92	3.2	52
50	Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice. <i>Journal of Cardiac Failure</i> , <b>2005</b> , 11, 91-8	3.3	100
49	Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial. <i>Journal of the American College of Cardiology</i> , <b>2005</b> , 46, 2329-34	15.1	178
48	Impact of nonfatal myocardial infarction on outcomes in patients with advanced heart failure and the effect of bucindolol therapy. <i>American Journal of Cardiology</i> , <b>2005</b> , 95, 558-64	3	12
47	Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. <i>Circulation</i> , <b>2005</b> , 112, 1121-7	16.7	195
46	C-reactive protein in heart failure: prognostic value and the effect of valsartan. <i>Circulation</i> , <b>2005</b> , 112, 1428-34	16.7	329
45	Pathogenesis of anemia in cardiorenal disease. <i>Reviews in Cardiovascular Medicine</i> , <b>2005</b> , 6 Suppl 3, S13-21	3.9	6
44	Anemia and its relationship to clinical outcome in heart failure. <i>Circulation</i> , <b>2004</b> , 110, 149-54	16.7	314
43	Syndromes of subacute mountain sickness. <i>High Altitude Medicine and Biology</i> , <b>2004</b> , 5, 156-70	1.9	35
42	The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. <i>European Heart Journal</i> , <b>2004</b> , 25, 292-9	9.5	262
41	Is too much neurohormonal blockade harmful?. <i>Current Cardiology Reports</i> , <b>2004</b> , 6, 169-75	4.2	4
40	Critical stenosis of aortic and mitral valves after mediastinal irradiation. <i>Catheterization and Cardiovascular Interventions</i> , <b>2004</b> , 63, 247-50	2.7	13
39	Long-term caspase inhibition ameliorates apoptosis, reduces myocardial troponin-I cleavage, protects left ventricular function, and attenuates remodeling in rats with myocardial infarction. <i>Journal of the American College of Cardiology</i> , <b>2004</b> , 43, 295-301	15.1	123
38	Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data. <i>Journal of the American College of Cardiology</i> , <b>2004</b> , 43, 2022-7	15.1	171
37	Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , <b>2004</b> , 364, 347-54	4.0	275
36	Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial. <i>Circulation</i> , <b>2003</b> , 108, 1306-9	16.7	85

35	The role of arginine vasopressin and its receptors in the normal and failing rat heart. <i>Journal of Molecular and Cellular Cardiology</i> , <b>2003</b> , 35, 495-504	5.8	25
34	Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). <i>Circulation</i> , <b>2003</b> , 107, 1278-83	16.7	698
33	Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). <i>Circulation</i> , <b>2002</b> , 106, 2454-8	16.7	259
32	Surrogate end points in heart failure. <i>Journal of the American College of Cardiology</i> , <b>2002</b> , 39, 1414-21	15.1	120
31	Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. <i>Journal of the American College of Cardiology</i> , <b>2002</b> , 40, 1414-21	15.1	271
30	Role of brain natriuretic peptide in the diagnosis and management of heart failure: current concepts. <i>Journal of Cardiac Failure</i> , <b>2002</b> , 8, 288-99	3.3	39
29	Noninvasive assessment of left ventricular remodeling: concepts, techniques, and implications for clinical trials. <i>Journal of Cardiac Failure</i> , <b>2002</b> , 8, S452-64	3.3	36
28	Ventricular remodeling without cellular contractile dysfunction. <i>Journal of Cardiac Failure</i> , <b>2002</b> , 8, S401-8	3.3	14
27	High Output Cardiac Failure. <i>Current Treatment Options in Cardiovascular Medicine</i> , <b>2001</b> , 3, 151-159	2.1	65
26	Letter from the Siachen Glacier. <i>High Altitude Medicine and Biology</i> , <b>2001</b> , 2, 553-7	1.9	4
25	Myocyte response to beta-adrenergic stimulation is preserved in the noninfarcted myocardium of globally dysfunctional rat hearts after myocardial infarction. <i>Circulation</i> , <b>2000</b> , 102, 1840-6	16.7	23
24	Cardiomyocytes from hearts with left ventricular dysfunction after ischemia-reperfusion do not manifest contractile abnormalities. <i>Journal of the American College of Cardiology</i> , <b>1999</b> , 34, 594-602	15.1	20
23	Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group. <i>Circulation</i> , <b>1999</b> , 99, 2658-64	16.7	175
22	Acute and chronic effects of propionyl-L-carnitine on the hemodynamics, exercise capacity, and hormones in patients with congestive heart failure. <i>Cardiovascular Drugs and Therapy</i> , <b>1998</b> , 12, 291-9	3.9	59
21	Effects of inhaled nitric oxide and oxygen in high-altitude pulmonary edema. <i>Circulation</i> , <b>1998</b> , 98, 2441-5	16.7	73
20	Mechanisms and management of renal dysfunction in heart failure. <i>Current Opinion in Cardiology</i> , <b>1997</b> , 12, 251-8	2.1	16
19	Isolated myocyte contractile function is normal in postinfarct remodeled rat heart with systolic dysfunction. <i>Circulation</i> , <b>1997</b> , 96, 3974-84	16.7	82
18	Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. <i>Circulation</i> , <b>1997</b> , 96, 856-63	16.7	219

17	Effects of A1 adenosine receptor agonism using N6-cyclohexyl-2SO-methyladenosine in patients with left ventricular dysfunction. <i>Circulation</i> , <b>1996</b> , 94, 1212-5	16.7	10
16	Endothelium-derived relaxing factor is important in mediating the high output state in chronic severe anemia. <i>Journal of the American College of Cardiology</i> , <b>1995</b> , 25, 1402-7	15.1	91
15	Utilization of propionyl-L-carnitine for the treatment of heart failure. <i>Developments in Cardiovascular Medicine</i> , <b>1995</b> , 323-335		2
14	Antistreptokinase antibodies before and after streptokinase therapy in patients with acute myocardial infarction from areas endemic for streptococcal infection and influence on reperfusion rates. <i>American Journal of Cardiology</i> , <b>1994</b> , 74, 187-9	3	18
13	Rate-dependent hemodynamic responses during incremental atrial pacing in chronic constrictive pericarditis before and after surgery. <i>American Journal of Cardiology</i> , <b>1993</b> , 72, 615-9	3	3
12	Balloon dilation of postoperative persistent coarctation of aorta and valvular aortic stenosis--a case report. <i>Angiology</i> , <b>1992</b> , 43, 614-7	2.1	1
11	Atrial fibrillation following electrical injury. <i>International Heart Journal</i> , <b>1992</b> , 33, 131-4		7
10	Active infective endocarditis observed in an Indian hospital 1981-1991. <i>American Journal of Cardiology</i> , <b>1992</b> , 70, 1453-8	3	52
9	Effects of prolonged infusion of human alpha calcitonin gene-related peptide on hemodynamics, renal blood flow and hormone levels in congestive heart failure. <i>American Journal of Cardiology</i> , <b>1991</b> , 67, 732-6	3	70
8	Lack of pain during myocardial infarction in diabetics--is autonomic dysfunction responsible?. <i>American Journal of Cardiology</i> , <b>1991</b> , 68, 793-6	3	18
7	Effect of dialysis and renal transplantation on autonomic dysfunction in chronic renal failure. <i>Kidney International</i> , <b>1991</b> , 40, 489-95	9.9	75
6	Cardiovascular and hormonal effects of calcitonin gene-related peptide in congestive heart failure. <i>Journal of the American College of Cardiology</i> , <b>1991</b> , 17, 208-17	15.1	30
5	Profile of right-sided endocarditis: an Indian experience. <i>International Journal of Cardiology</i> , <b>1991</b> , 33, 83-8	3.2	16
4	Enalapril as initial and sole treatment in severe chronic heart failure with sodium retention. <i>International Journal of Cardiology</i> , <b>1990</b> , 28, 341-6	3.2	19
3	Balloon dilatation of double-chamber right ventricle. <i>American Heart Journal</i> , <b>1990</b> , 120, 1234-6	4.9	14
2	Cost of antihypertensive treatment: a point of view from India. <i>Cardiovascular Drugs and Therapy</i> , <b>1989</b> , 3, 761-5	3.9	
1	Swallowing induced supraventricular ectopics in a patient with straight back syndrome. <i>International Heart Journal</i> , <b>1989</b> , 30, 523-6		7